alpelisib
1. Basic Product Identification
INN Name: Alpelisib
Brand Name: Piqray
Therapeutic Class: PI3K inhibitor (PI3Kα selective)
Route: Oral (tablet)
Target Therapy Area: Oncology (breast cancer)
Primary indication:
HR-positive HER2-negative breast cancer with PIK3CA mutation
2. Therapeutic Knowledge
Alpelisib is used in:
Advanced/metastatic breast cancer
Always in combination with fulvestrant
For PIK3CA-mutated tumors only
Key concept:
???? First-in-class PI3Kα isoform-specific targeted therapy
3. Mechanism of Action (MOA)
Alpelisib selectively inhibits PI3K alpha (PI3Kα).
Pathway:
Blocks PI3K → AKT → mTOR signaling cascade
Effects:
↓ tumor cell proliferation
↓ survival signaling
Induces apoptosis in PIK3CA-mutant cancer cells
Key insight:
???? Targets driver mutation pathway in oncogenesis
4. Pharmacokinetics (ADME)
Absorption
Oral bioavailability moderate
Food has minimal clinically significant effect
Distribution
Moderate plasma protein binding (~80%)
Metabolism
Primarily hepatic metabolism (CYP3A4 involvement minor)
Excretion
Fecal (major)
Urinary (minor)
Half-life:
~8–9 hours
5. Dosage & Administration
Standard regimen:
300 mg once daily (oral tablet)
Combination:
Always with fulvestrant (endocrine therapy)
Administration rules:
Take with food
Same time daily
Dose reduction required in toxicity (hyperglycemia management)
6. Formulation Knowledge
Dosage form:
Film-coated oral tablets
Key formulation challenges:
Low solubility
High-dose strength (oncology dosing)
Stability in humid environments
Technologies used:
Solid dispersion
Particle size reduction
Film coating for stability
7. Raw Materials Knowledge
API:
Alpelisib (synthetic small molecule kinase inhibitor)
Excipients:
Microcrystalline cellulose
Mannitol
Sodium starch glycolate
Magnesium stearate
Film coating polymers (HPMC-based)
Critical issues:
Control of polymorphism
Impurity control (genotoxic impurity risk monitoring)
8. Manufacturing Process Knowledge
API synthesis:
Multi-step heterocyclic organic synthesis
Kinase inhibitor scaffold construction
Purification via crystallization & chromatography
Tablet manufacturing:
Blending (API + excipients)
Dry granulation preferred (stability)
Compression
Film coating
Critical controls:
Uniformity (high-dose oncology tablet)
Impurity profile control (ICH Q3A/Q3B strict)
9. Analytical & QC Knowledge
Key QC tests:
HPLC assay
Impurity profiling (trace-level sensitivity)
Dissolution testing (biorelevant media)
Content uniformity
Water content (KF)
Residual solvents (GC)
Advanced techniques:
LC-MS/MS for impurity tracking
Stability-indicating methods
10. Regulatory Knowledge
Approval status:
FDA approved (targeted oncology indication)
EMA approved
Regulatory requirements:
Companion diagnostic required (PIK3CA mutation test)
Oncology clinical trial package (Phase I–III)
Risk management plan (RMP)
Labeling requirements:
Severe hyperglycemia warning
Rash and pneumonitis risk
Embryo-fetal toxicity warning
11. Storage & Stability
Store at 20–25°C
Protect from moisture
Shelf life: ~24 months
Stability risks:
Humidity-induced degradation
Polymorphic changes
Photostability generally acceptable
12. Packaging Knowledge
Alu-Alu blister packs (moisture protection)
High-barrier HDPE bottles (some markets)
Oncology safety packaging (child-resistant optional but common)
13. Safety & Toxicology
Common adverse effects:
Hyperglycemia (dose-limiting)
Rash
Diarrhea
Fatigue
Nausea
Serious risks:
Severe hyperglycemia → ketoacidosis risk
Pneumonitis
Severe hypersensitivity reactions
Monitoring:
Blood glucose (mandatory)
HbA1c baseline & follow-up
14. Market & Commercial Knowledge
Market type:
Precision oncology / targeted therapy market
Competition:
Endocrine therapy combinations
CDK4/6 inhibitors (different pathway)
Other PI3K inhibitors (limited due to toxicity issues)
Key driver:
Companion diagnostic-based prescription model
15. Intellectual Property (IP)
Strong composition-of-matter patent (Novartis origin)
Companion diagnostic exclusivity supports lifecycle extension
Secondary patents:
Combination therapy
Specific dosing regimens
16. Environmental & EHS Knowledge
Potent cytotoxic/oncology handling precautions
API manufacturing requires containment systems
Waste:
Genotoxic waste classification possible
Worker safety:
Closed-system handling recommended
17. Export Documentation Knowledge
Required:
DMF (Type II API)
GMP certificate (high-potency API compliance)
COA (batch release)
Stability studies (ICH Q1A)
Genotoxic impurity assessment
Bioequivalence study (generic)
MSDS (cytotoxic handling guidance)
18. Business Development Knowledge
Opportunities:
Oncology hospital supply chains
Precision medicine oncology programs
Emerging markets oncology expansion
Strategy:
Partner with diagnostic labs (mutation testing)
Oncology specialist physician networks
Value-based pricing (high-cost therapy)
19. Advanced Technical Knowledge
PI3K pathway is central to tumor survival signaling
Mutation-specific therapy = precision oncology Argentina model
Resistance mechanisms include pathway reactivation
Hyperglycemia mechanism linked to insulin signaling interference
Narrow therapeutic index in real-world use
20. AI & Digital Knowledge (Modern Pharma)
AI applications:
Companion diagnostic prediction models
Oncology response prediction (mutation-driven ML models)
Real-world evidence (RWE) tracking
Pharmacovigilance signal detection (hyperglycemia risk patterns)
Digital pharma:
Genomic-guided prescription platforms
Hospital oncology decision-support systems
21. Sales Team Product Knowledge Checklist
Sales teams must know:
Only for PIK3CA-mutated breast cancer
Always combined with fulvestrant
Blood glucose monitoring requirement
High toxicity management importance
Companion diagnostic necessity
22. Most Important Technical Documents
DMF (API + formulation)
Clinical trial data (SOLAR-1 study)
Companion diagnostic validation reports
Stability studies (ICH Q1A)
Impurity profiling (ICH Q3A/B)
Genotoxicity assessment
Risk Management Plan (RMP)
GMP certificate
23. Ultimate Pharma Product Mastery Summary
Alpelisib is:
A precision oncology PI3Kα inhibitor
Technically complex due to:
High-dose oral formulation
Toxicity management (hyperglycemia)
Commercially advanced due to:
Companion diagnostic-driven therapy
High-value oncology market
Clinically important in:
Mutation-driven breast cancer treatment